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ABSTRACT 
Background 
Idiopathic Pulmonary Fibrosis (IPF), a progressive and inevitably fatal disorder, has a highly variable 
clinical course. Biomarkers which reflect disease activity are urgently needed to inform patient 
management and as biomarkers of therapeutic response (theragnostic biomarkers) in clinical trials.  
We examined whether dynamic change in markers of extracellular matrix (ECM) turnover predicts IPF 
disease behaviour in the PROFILE study cohort. 
Methods 
Serum samples from 189 patients with incident IPF, prospectively collected at baseline, one, three and 
six months as part of the PROFILE study, were analysed for a panel of novel matrix metalloprotease 
(MMP)-degraded ECM proteins, by ELISA-based, neoepitope assay. Eleven neoepitopes were tested 
in a discovery cohort of 55 patients to identify biomarkers of sufficient rigor for more detailed 
analyses. Eight were then further assessed in a validation cohort of 134 patients with 50 age and 
gender matched controls. Changes in biomarker levels were related to subsequent progression of IPF 
(defined as death or decline in forced vital capacity >10% at 12 months following study enrolement). 
Findings 
In the discovery cohort mean levels of seven neoepitopes (BGM, C1M, C3M, C6M, CRPM, ELM2 and 
VICM) differed significantly between healthy controls and IPF subjects. Baseline levels of six 
neoeptiopes (C1M, C3A, C3M, C6M CRPM and VICM) were significantly higher in progressive versus 
stable disease. In the validation cohort, mean levels of C1M, C3M, C6M and CRPM at baseline were 
confirmed to be higher in IPF patients compared with healthy controls. When assessed longitudinally 
levels of six neoepitopes (BGM, C1M, C3A, C3M, C6M, CRPM) were significantly higher in progressive 
compared with stable patients by six months.  Baseline levels of two neoepitopes (C1M: HR 1.62 95% 
CI 1.14–2.31, p=0.007 and C3A: HR 1.91 95% CI 1.06–3.46, p=0.032) were associated with increased 
mortality. The rate of change over three months of six neoepitopes (BGM, C1M, C3M, C5M, C6M and 
CRPM) was strongly predictive of overall survival, and furthermore the increased risk was proportional 
to the magnitude of change in neoepitope levels. The strongest relationship with three-month rate of 
change was observed for CRPM for which a Δ> 0 ng/ml/month conferred a HR of 2.16 (95% CI 1.15–
4.07) whilst a Δ> 1 ng/ml/month resulted in an HR 4.08 (95% CI 2.14-7.8) and a Δ> 1.7 ng/ml/month 
was associated with an HR 6.61 (95%CI 2.74-15.94).   
Interpretation 
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Protein fragments generated by MMP activity are elevated in the serum of individuals with IPF 
compared with controls. Neoepitope levels increase with disease progression and the rate of this 
increase predicts survival. Serial measurements of neoepitopes have potential to be used as 
theragnostic biomarkers in clinical trials and to guide management in IPF. 
Funding 
GlaxoSmithKline R&D and MRC Industrial Collaborative Award with GlaxoSmithKline R&D 
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INTRODUCTION  
Idiopathic pulmonary fibrosis (IPF) is a progressive and inevitably fatal disease with a 5 year survival 
of only 20%1. With the advent of specific anti-fibrotic medications there is now hope that disease-
modification and improved survival may be realistic therapeutic goals2, 3. Advances in IPF management 
are, however, hampered by heterogeneity of disease behaviour, a lack of validated prognostic 
measures and the absence of any markers of treatment response4. Novel serum biomarkers of 
fibroproliferation are emerging across a range of non-pulmonary diseases but none have been 
prospectively validated in carefully phenotyped individuals with IPF. 
A cardinal feature of IPF is the accumulation of disordered and architecturally disruptive extracellular 
matrix (ECM) within the lung. The ECM consists of a dynamic combination of structural proteins, the 
most abundant of which are collagens. Matrix turnover is determined by several factors including the 
rate of ECM synthesis by activated myofibroblasts, the extent of collagen cross-linking and enzymatic 
matrix degradation5.  Biomarkers reflective of matrix turnover might therefore be indicative of disease 
activity in fibroproliferative disorders such as IPF.  
The majority of extracellular collagen is degraded by a subset of matrix metalloproteinases (MMPs) 
including MMP-1, -3, -7, -8, -13, -14, -16 and -186. Extracellular collagen fragments generated by these 
MMPs are then further digested by MMP-2 and -96. In IPF markedly increased rates of ECM protein 
synthesis are, at least partially, offset by elevated MMP levels and activity7 and MMP-1, -3 and -7 have 
even been identified as putative prognostic serum biomarkers8, 9. 
During ECM turnover, proteolytically cleaved matrix degradation fragments, or neoepitopes, are 
released into the systemic circulation10.  Cleavage of each ECM protein by specific MMPs generates a 
unique neoepitope. These neoepitopes have been shown to be more accurate diagnostic and 
prognostic markers for individual fibroproliferative diseases than their protein of origin10, 11.  Previous 
small point-of-diagnosis studies have suggested that matrix neoepitopes may be elevated in 
individuals with IPF compared with healthy controls12-14. 
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The PROFILE (Prospective Observation of Fibrosis in the Lung Clinical Endpoints) study is the largest 
prospective study of its kind undertaken to date. To our knowledge, this study enables, for the first 
time, sequential assessment of biomarkers over time in relation to clinical measures of disease activity 
and progression. Furthermore, the recruitment of incident IPF cases from multiple centres enhances 
the potential applicability of any findings to real-world clinical practice. This analysis of samples from 
the first 189 PROFILE subjects with IPF was undertaken to determine the prognostic value of 
longitudinal change in serum levels of proteolytically cleaved protein fragments, or neoepitopes.   
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METHODS 
Participants 
The PROFILE study is an ongoing prospective, multi-centre, observational cohort study of incident 
cases (within 6 months of presentation) of idiopathic fibrotic lung disease. For all subjects clinical, 
physiological and biochemical data were collected at baseline and at one, three, six, 12 months, 24 
and 36 months. Participants with IPF or idiopathic NSIP were identified through two co-ordinating 
centres: Nottingham, UK and, Royal Brompton Hospital, London, UK. For the purpose of this analysis 
samples from confirmed IPF cases drawn from the first 214 subjects enrolled during the first 18 
months of the study were examined.  Mortality data were collected from the NHS registry with a date 
of censoring of 1st October 2013. Only subjects with a multidisciplinary team confirmed diagnosis of 
IPF made in accordance with current internationally accepted criteria15 were included in the current 
study. 
Study Design 
A two-stage study design was used to facilitate rational stop-go decision making in order to minimise 
unnecessary waste of patient samples. Initial analysis was performed on a discovery cohort of 55 
individuals with IPF drawn from the first 100 subjects recruited into the study enriched for the mildest 
and most severe disease and compared with gender matched controls for benchmarking purposes. 
Analysis of data from the discovery cohort was undertaken prior to a complete detailed analysis of a 
validation cohort, consisting of the remaining 134 IPF patients. 70 physician-verified, control subjects 
without history of respiratory disease were recruited from primary care clinics and provided a single 
serum sample. 50 of these subjects, analysed alongside the validation cohort, were age and gender 
matched to the PROFILE study recruits. All individuals provided written informed consent.  The 
PROFILE study is registered on clinicaltrials.gov (NCT01134822 and NCT01110694). 
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The discovery analysis was limited to assessment of baseline matrix neoepitope levels with 
comparison of subjects and controls and subjects with IPF dichotomised into those with progressive 
or stable disease. Neoepitopes were selected for testing in the validation cohort if the following 
conditions were met: the assay was sufficiently robust to have <1%  of data falling outside the upper 
or lower limits of detection; and the difference between stable and progressive disease was significant 
at the 10% level.  
Procedures 
Serum samples collected from PROFILE study subjects at baseline, one, three and six months and 
single samples from control subjects were stored at −80 °C until assayed. Collection was standardised 
across centres by using agreed Standardised Operating Procedures. Blood was collected using anti-
coagulant free, serum separation tubes (Becton Dickenson, Oxford, UK) which uses coated silica as the 
clot activator. All samples were processed within two hours of collection. Samples were allowed to 
clot at room temperature over 30 minutes. Serum was separated by centrifugation and aliquoted prior 
to freezing. A unique aliquot was used for neoepitope analyses to avoid repeated freeze-thaw. Serum 
levels of biglycan degraded by MMP-2/9 (BGM), collagen 1 degraded by MMP-2/9/13 (C1M), collagen 
3 degraded by MMP-9 (C3M), collagen 3 degraded by ADAMTS-1/4/8 (C3A), collagen 5 degraded by 
MMP-2/9 (C5M), collagen 6 degraded by MMP-2/9 (C6M), C-reactive protein degraded by MMP-1/8 
(CRPM), Elastin degraded by MMP-12 (ELM), elastin degraded by MMP-9/12 (ELM2), the synthetic 
marker for collagen 3 (P3NP) and citrullinated vimentin degraded by MMP-2/8 (VICM) were measured 
as previously described12. The performance characteristics of the assays and non-standard 
abbreviations are shown in supplementary table 1. 
Measurements of forced vital capacity (FVC) and DLco were recorded, at baseline, 6 and 12 months, 
as absolute and percent predicted values based on the European Coal and Steel Board reference 
equations using age and height at the baseline visit16.  
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Statistical analysis  
Disease progression was defined as all-cause mortality or ≥10% decline in FVC at 12 months. In cases 
where 12 month FVC data were absent, subjects were considered to have progressed if a ≥10% decline 
in FVC was observed at 6 months. Where no lung function data were available beyond baseline, cases 
were adjudicated, following case note review, by the local principal investigator blinded to biomarker 
results. Missing lung function data were not imputed. In cases where biomarker data were below the 
lower limit of detection, values were imputed to be half the lower limit of detection. Values above the 
upper limit were conservatively imputed as the upper limit of detection. Except where stated the 
percentage of imputed data was below 1% of all measurements for each biomarker. Sensitivity 
analysis was performed demonstrating that data imputation did not alter the impact of the reported 
findings. For serial biomarker data, change from baseline for each subject is represented by a gradient 
on a linear model where the single explanatory variable is the number of months between the baseline 
visit and subsequent visits using the recorded visit date.  
Prior to performing any association analysis, relevant variables were assessed for normality.  Skewed 
data were transformed using the base 10 or base 2 logarithms. When comparing baseline biomarker 
values between control and IPF groups adjusted estimates of group means, differences and 
confidence intervals were obtained using a general linear model with age, gender and group as 
explanatory variables. The nature of the variation of biomarkers over time was evaluated in the 
validation population.  A repeated-measures, mixed effects model was used with biomarker value as 
the dependent variable and progression status, visit and visit by progression status as explanatory 
variables.  The covariance structure was constrained for measurements which were repeated within 
subject, with visit as a repeated effect and with an unstructured covariance matrix. Least Squares 
estimates were used to obtain the means and confidence intervals for each biomarker in each 
progression status and visit group and for the difference in biomarker means between progression 
and stable groups.  Survival analysis was performed using a Cox proportional hazards model to assess 
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the association between continuous explanatory variables and overall survival. Multivariate analysis 
was undertaken with a stepwise selection method within a Cox regression model with entry criterion 
set to p<0.1 and stay criterion set to p<0.2.  Survival analysis was performed for baseline biomarker 
and lung function measures and for biomarker gradients.  Further analysis was performed to evaluate 
the impact of applying different thresholds to dichotomise explanatory variables in the survival 
analysis.  Potential thresholds for biomarker gradients were selected by identifying unique values for 
each gradient, ordering by value, iteratively setting a threshold to each value and estimating the 
hazard ratio for subjects above the threshold compared with those below    
Associations between explanatory variables and endpoints were declared significant at the 5% level.  
As the study comprises a biomarker discovery and validation cohort, there has been no adjustment 
for multiple testing within each cohort.  All statistical analyses were performed using SAS version 9.2 
and were validated by independent replication. 
Role of the funding source 
The PROFILE study was funded by the Medical Research Council (G0901226) and GlaxoSmithKline R&D 
(CRT114316), and was sponsored by Nottingham University and Royal Brompton and Harefield NHS 
Foundation Trust. Analysis of neoepitope biomarkers was conducted by Nordic Biosciences with 
funding from GlaxoSmithKline R&D. Investigators received no financial incentives from the funding 
sources. GlaxoSmithKline R&D participated in study design, co-ordination of biomarker analysis, and 
statistical analysis. TMM and RGJ were involved in all stages of study development and delivery, had 
full access to all data in the study and had final responsibility for the decision to submit for publication. 
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RESULTS 
Of the 214 eligible subjects, recruited between September 2010 and March 2012, 189 had a confirmed 
diagnosis of IPF and were included in subsequent analyses (figure 1). These subjects (table 1 and 
supplementary table 2) were predominantly male (78.8%) with a mean age of 70.1 ± 8.3 years. Patients 
from the Royal Brompton Hospital were significantly younger than patients from Nottingham 
University Hospitals and had slightly, but significantly worse lung function (supplementary table 2). 
184 participants had baseline FVC data. 148 of these individuals had available 12-month FVC data. 
Repeated measures of FVC were unavailable due to death in 23 cases. 16 of the remaining 18 subjects 
missing a 12-month FVC had sufficient available clinical data to assign a progression status.  
11 neoepitopes were measured in the discovery cohort of 55 subjects and a group of 20 healthy 
gender-matched (80% male) controls with a mean age of 56.6 ± 4.6 years. Levels of seven of the matrix 
neoepitopes (BGM, C1M, C3M, C6M, CRPM, ELM2, and VICM) differed significantly between healthy 
controls and individuals with IPF (supplementary figure 2). To determine the relationship between 
baseline neoepitope levels and subsequent disease behaviour, subjects with IPF were dichotomised, 
based on 12-month outcome, in to those with stable (n=23) or progressive (n=32) disease. Levels of 
six neoeptiopes (C1M, C3A, C3M, C6M, CRPM and VICM) were significantly higher at baseline in 
individuals with progressive disease compared with those with stable disease (figure 2).  However, in 
an unadjusted analysis of the discovery cohort (Table 2) only baseline CRPM significantly associated 
with decreased survival time (HR 3.74 95% CI 1.46 – 9.58, p = 0.006). Baseline FVC (HR 0.09 95% CI 
0.03 – 0.27, p<0.001) and DLco (HR 0.19 95% CI 0.08 – 0.42, p<0.001) were also both strongly 
associated with survival. In multivariable analysis only baseline DLco remained a significant 
independent predictor of survival.  
Following analysis of the discovery cohort, eight neoepitopes (BGM, C1M, C3A, C3M, C5M, C6M, 
CRPM and VICM) were measured in a validation cohort of 134 individuals with IPF and 50 age- and 
gender-matched healthy controls. In keeping with the results from the discovery cohort, baseline 
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levels of C1M, C3M, C6M and CRPM were significantly higher in IPF subjects than in healthy controls 
(supplementary figure 2). In contrast with the discovery cohort, at baseline, none of the neoepitopes 
showed a statistically significant difference between stable and progressive subjects. However, pooled 
analyses suggested five neoepitopes (C3A, C3M, C6M, CRPM, VICM) could discriminate between 
stable and progressive disease (supplementary figure 3). Analysis of serial samples demonstrated that 
by six months levels of BGM, C1M, C3A, C3M, C6M and CRPM were significantly higher in individuals 
with progressive IPF compared with those with stable disease (figure 3 and supplementary figure 4). 
Unadjusted analysis of the validation cohort demonstrated that baseline C1M (HR 1.62 95% CI 1.14–
2.31, p=0.007) and C3A (HR 1.91 95% CI 1.06–3.46, p=0.032) together with FVC (HR 0.27 95% CI 0.10–
0.70, p=0.007) and DLco (HR 0.18 95% CI 0.10–0.34, p<0.001) significantly associated with decreased 
survival (Table 2). Baseline CRPM, which showed an association in the discovery cohort, trended 
towards an association with survival in the validation cohort (HR1.87 95% CI 0.98-3.56, p=0.058). 
Again, on multivariable analysis DLco remained the only significant baseline predictor of survival. 
To understand the relevance of temporal variations in neoepitope values, the rate of biomarker 
change (Δ) over three months was calculated for each subject. An increasing rate of change of six 
neoepitopes (BGM; C1M; C3M; C5M; C6M; CRPM) indicated poorer overall survival (figure 4). After 
dichotomisation of subjects in to those with rising levels of each neoepitope over 3 months (Δ>0 
ng/ml/month) or those with a stable or falling neoepitope level (Δ≤0 ng/ml/month) the unadjusted 
mortality rate was significantly higher in subjects with rising levels of C1M, C5M, C6M and CRPM 
compared with stable or falling levels (figure 4).  The greatest effect size was seen for CRPM (HR 2.16 
CI 1.15–4.07, p <0.001). After adjustment for other covariates (age, gender, site, smoking status and 
baseline % predicted FVC and DLco), the individual rates of change over three months of C1M, C3M, 
C5M, C6M and CRPM were each significant independent predictors of overall survival (supplementary 
table 4). With the exception of CRPM, the relationship between temporal rate of change and 
subsequent outcome was less apparent after only a month, but was strengthened further by inclusion 
of six month neoepitope values (supplementary table 5). 
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To explore the effect of magnitude of the rate of change of neoepitope level on survival, the hazard 
ratio for overall survival was estimated at differing thresholds for rate of change at three months by 
comparing survival in patients with changes above and those below the threshold (figure 5). The most 
striking relationship with threshold was observed for CRPM for which a Δ> 0 ng/ml/month conferred 
a HR of 2.16 (95% CI 1.15–4.07) whilst a Δ> 1 ng/ml/month resulted in an HR 4.08 (95% CI 2.14-7.8) 
and a Δ> 1.7 ng/ml/month was associated with an HR 6.61 (95%CI 2.74-15.94).   
 13 
DISCUSSION 
The PROFILE study is the largest prospective cohort study of incident idiopathic fibrotic lung disease 
conducted to date. It has enrolled patients with incident fibrotic lung disease of all severities, through 
two co-ordinating centres, with all subjects included in the current analysis being naïve for anti-fibrotic 
therapy. The slightly younger, but more severe, cohort from the Royal Brompton hospital probably 
reflects its role as a national tertiary referral centre, whereas the patients seen at regional hospitals, 
co-ordinated through Nottingham, represent truly unselected patients reflective of those seen in 
secondary care centres. This has generated a unique, prospective data set collected at pre-specified 
time intervals from incident cases of IPF. As such, to our knowledge, it is the first study to demonstrate 
that disease progression and subsequent outcome in IPF can be determined by detecting temporal 
change in the levels of circulating proteins. This analysis of the PROFILE dataset demonstrates proof 
of principle that serial longitudinal measurement of serum markers provides important information 
over and above single point in time measures, and furthermore may address the critical unmet need 
in the field of IPF research for prognostic biomarkers of molecular phenotype or therapeutic response 
(theragnostic biomarkers).  
Serum biomarkers are unlikely to usurp high resolution computerised tomography (HRCT) in the 
diagnosis of IPF. Biomarker levels obtained at baseline may, however, facilitate management decisions 
in cases of unclassifiable, progressive fibrotic lung disease through identification of molecular 
phenotypes of disease predictive of response to anti-fibrotic therapies. It seems unlikely that baseline 
serum biomarker levels will outperform existing physiological measures of disease severity. Our data 
confirm the prognostic importance of baseline FVC and DLco17,18.  Whilst longitudinal change in these 
physiological measures of IPF disease severity associate with worsening fibrosis they do so only after 
a minimum of six or 12 months19-21. Furthermore, the value of serial DLco is hampered by 
measurement variability both within subjects (which has been shown to be as great as 15% in serial 
measures obtained in healthy individuals22), and between lung function laboratories, and the 
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confounding effects of pulmonary hypertension. Additionally, unlike serum biomarkers, physiological 
biomarkers provide no insights in to disease mechanism and are thus unable to identify distinct 
molecular phenotypes of disease.  
A lack of short term measures of change in disease activity has hampered the development of early 
phase clinical trials in IPF23. Importantly, therefore, we show that changes in the levels of six 
neoepitopes (BGM, C1M, C3M, C5M, C6M and CRPM) over time strongly associate with outcome. 
Moreover, the magnitude of change of the values of these neoepitopes associate strongly with 
subsequent survival. Vitally, for each neoepitope, change over only three months was predictive of 
subsequent outcome. The observed relationship between rate of change in serum neoepitope levels 
and outcome suggests that these markers may have the potential for use as surrogate clinical trial 
endpoints and could therefore transform early phase clinical trial design in IPF. It is also tempting to 
speculate that measurement of neoepitopes could aid clinical decision-making in IPF. With the 
approval of both pirfenidone and nintedanib in the US and Europe there is, for the first time, a choice 
of anti-fibrotic treatments. Both drugs have been shown to slow disease progression, but are not 
anticipated to halt or reverse IPF. Therefore, in a disease that displays variable rates of progression 
there is now a desperate need for theragnostic biomarkers to define, for individual patients, treatment 
‘success’ and ‘failure’ to thus enable clinicians to make rational decisions regarding treatment 
initiation and discontinuation. Appropriately designed interventional trials, utilising either pirfenidone 
or nintedanib, will be required to determine whether serial measurement of neoepitopes predicts 
treatment response. The development of proven theragnostic markers for IPF has the potential to 
shorten clinical trials and to enable better delivery of patient care. Measuring matrix neoepitope levels 
could enable patients to avoid unnecessary adverse events and prevent irreversible lung function loss 
whilst reducing the economic cost of persevering with ineffective therapy.  
Measurement of neoepitopes provides an indirect mechanism for determining the activity of 
degradative proteolytic enzymes10.  In keeping with our data, Leeming et al have previously shown 
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C1M, C3M, and C6M to be elevated at diagnosis in serum from 30 individuals with IPF compared with 
15 unmatched controls12. The markers chosen for this study were selected specifically to identify 
metalloproteinase cleavage products (together with a single marker of collagen synthesis) with the 
intention of indirectly assessing ECM turnover in IPF. Several strands of evidence suggest that MMP 
activity is upregulated in IPF. MMPs -1, -2, -3, -7, -8 and -9 have been shown to be elevated in the 
serum, lung tissue and lavage fluid of subjects with IPF7, 8, 24, 25. Furthermore, MMP-9, measured at the 
RNA level in whole lung homogenate and the protein level in BAL, discriminates between stable and 
progressive cases of IPF25. Activation of MMPs is associated with increased fibroproliferation in both 
in vitro and in vivo studies7, 26. Furthermore, neoepitope levels have been shown to track the evolution 
of fibrosis in tissue sections13. It is, therefore, tempting to speculate that increased MMP activity alone 
is responsible for the rising neoepitope levels observed in progressive IPF. However, whilst C1M, C3M, 
C5M, C6M, ELM, ELM2 and VICM are all degraded by MMP-2 or -9 we found that serum levels of these 
different neoepitopes vary in their relationship to IPF disease progression. A possible explanation for 
our observations are that increased activity of collagenases (MMP-1,-3,-7 and -8) generate increased 
substrate for the gelatinases (MMP-2 and -9). This supposition is supported by the strongest 
association being found with CRPM. Further experimental data are needed, however, to confirm 
whether high levels of collagen neoepitopes reflect a phenotype of enhanced collagenase activity. 
Baseline assessment of a number of serum proteins (including MMP-7, CCL-18, SP-D and KL-6) have 
been shown to weakly predict subsequent disease behaviour in IPF8, 27-29. None of these proteins has, 
however, been assessed serially to determine whether change over time maps to worsening of 
underlying fibrosis. The PROFILE study was designed with the explicit aim of longitudinally 
phenotyping a carefully described cohort of individuals with idiopathic fibrotic lung disease (both IPF 
and idiopathic NSIP) with the intention of identifying markers of disease behaviour. Any such markers 
can then be tested for their potential as theragnostic biomarkers. A major strength of the study is that 
all patients with an incident diagnosis of IPF, irrespective of disease severity, were included and 
therefore the outcomes observed in our cohort mirror the true clinical experience of IPF. Further 
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strengths of this study relate to the size of the cohort, the two-stage design, the longitudinal sampling 
performed and the fact that longitudinal clinical data were available to determine disease outcomes 
in all but two subjects. As previously described the PROFILE cohort is the largest prospective biomarker 
study undertaken in therapy naïve, incident cases of IPF of all severity ranges. With the US and 
European approvals of pirfenidone and nintedanib it is unlikely that such a study will be repeated and 
thus the PROFILE study represents a unique and valuable resource.  Given the finite nature of the 
samples available, it was crucial that rational stop-go decision-making was used to assess the matrix 
neoepitopes. The discovery analysis was designed to maximise the chances of detecting plausible 
biomarkers. Whilst our study design increased the risk of false positive results, this was mitigated by 
utilisation of a validation cohort. Although we chose to undertake measurements in serum, matrix 
neoepitopes are considerably more stable than many other protein analytes and so, with the 
exception of VICM, they can also be measured in plasma and other biological fluids such as urine or 
bronchoalveolar lavage fluid30, 31. 
This study has some limitations. Because the discovery cohort was enriched for individuals with 
extremes of disease severity the validation cohort contains a disproportionate number of subjects 
with moderate disease. This may have reduced the power of our validation study to detect a 
relationship between neoepitopes and disease outcomes. Against this, however, mortality was similar 
in both the discovery and validation cohorts (supplementary figure 3) and, on association analysis, 
only BGM, C3M and ELM showed a relationship to baseline disease severity (data not shown). 
Furthermore, the observational nature of the PROFILE study precluded standardisation of therapy. 
However, sample collection occurred at a time when there were no approved IPF treatments routinely 
available in the UK and no patients were receiving pirfenidone for the duration of these analyses. 
Although many study subjects were on N-acetyl cysteine recent trial data suggest that this is unlikely 
to have influenced the natural history of the disease32. Whilst it would be reassuring to replicate our 
findings in a truly independent external validation cohort the unique nature of the PROFILE cohort 
means that this is unlikely to be possible. This is because other existing cohorts are considerably 
 17 
smaller; most have not collected serial samples; commercial clinical trials do not include patients of 
all severities and most have failed to routinely collect samples. Furthermore, as noted, it will not be 
possible to collect a future cohort of patients naïve for anti-fibrotic therapy. The lack of age-matched 
controls is a limitation of the discovery analysis. However, in these analyses results are adjusted to 
avoid age as a cofounding factor. More importantly, the data from control patients are not used to 
draw any conclusions rather they are presented to facilitate benchmarking and to provide context for 
the neoepitope values seen in IPF patients.  
In conclusion, to our knowledge, this is the first IPF biomarker study to combine longitudinal clinical 
data collection with serial biological sample collection from incident cases of IPF, with disease of any 
severity and naïve to anti-fibrotic therapy. Although, further data relating to serum measures from 
this cohort will become available in the future, this primary analysis of the cohort demonstrates that 
protein fragments generated by metalloproteinase activity identify individuals with IPF from healthy 
controls and, more importantly, the rate of change of five of these protein fragments over three 
months associates with disease worsening and predicts reduced survival. We believe that these 
neoepitopes have the potential to address an urgent unmet need in the management of IPF. Rising 
levels of matrix neoepitopes may identify a phenotype of IPF characterised by rapid matrix turnover 
and poor prognosis which may be more amenable to anti-fibrotic therapy. Furthermore, the 
neoepitopes identified in this study have the potential to be used as theragnostic biomarkers. Whilst 
this hypothesis requires testing in an appropriately designed, prospective, therapeutic trial the 
predictive prognostic value of the 3-month change in these markers promises the potential to radically 
shorten future clinical trials and also to help clinicians determine treatment efficacy. This is an issue 
of heightened importance now that we are entering an era of multiple approved anti-fibrotic 
therapies33. 
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Research in Context 
Systematic Review: We searched PubMed for reports before October 1 2014 with the search terms 
“idiopathic pulmonary fibrosis”,  “biomarkers” and “prognosis”. No language restrictions were 
applied.  At the time of our search, none of the published biomarker studies in IPF had assessed 
longitudinal change and only a small number had had been performed in similar sized cohorts (all of 
which were retrospectively assessed) to the one available through the PROFILE study.  
 
Interpretation: These data are the first output from the largest and most detailed prospective 
observational cohort study in IPF.  We demonstrate that a number of matrix-metalloproteinase 
degraded neoepitopes are elevated in the serum of individuals with IPF compared with age matched 
healthy controls. Importantly, three-month longitudinal change in six neoepitopes correlates with 
worsening disease and outcomes in subjects with IPF. Change in neoepitope levels predicts 
progression of fibrosis at an earlier stage than does decline in physiological parameters. 
Furthermore, magnitude of change relates to subsequent likelihood of disease worsening. Although 
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further studies are required, measurement of neoepitopes have the potential to be used as 
theragnostic biomarkers which could be of use in future trials and in clinical practice to define 
response to therapy.  
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Tables 
 Discovery (n=55) Validation (n=134) All subjects (n=189) 
Age (years) 68.5 (9.53) 70.7 (7.66) 70.1 (8.28) 
Male gender 
 
43 (78.2%) 106 (79.1%) 149 (78.8%) 
Ethnicity    
European 51 (92.7%) 127 (94.8%) 178 (94.2%) 
Asian 4 (7.3%) 6 (4.4%) 10 (5.3%) 
Other 
 
0 1 (0.7) 1 (0.5) 
Ever smokers 
 
40 (72.8%) n=54 94 (70.2%) 134 (70.9%) n=188 
BMI (Kg/m2) 
 
28.2 (4.84) 28.4 (4.20) 28.4 (4.39) 
Baseline lung function    
Mean FVC (% 
predicted) 
75.9 (23.46) n=53 78.1 (17.18) n=131 77.5 (19.16) n=184 
FVC 60≤90 % 
predicted 
24 (43.6%) 85 (63.5%) 109 (57.7%) 
Mean DLco (% 
predicted) 
44.4 (18.26) n=52 42.1 (13.51) n=124 42.8 (15.05) n=176 
DLco 40≤60 % 
predicted 
12(21.8%) 52 (38.8%) 64 (33.9%) 
CPI 
 
48.4 (16.42) n=52 49.7 (11.56) n=123 49.3 (13.15) n=175 
Median follow up 
(range) days  
792 (47 – 1071) 643.5 (24 – 1100) 673 (24 – 1100) 
Data are Mean (SD) or number (%) unless otherwise stated. BMI – Body mass index. FVC – 
forced vital capacity, DLco – diffusion capacity for carbon monoxide. CPI – Composite 
Physiological Index.  Moderate FVC defined as % predicted FVC between 60-90% inclusive.  
Moderate DLco defined as % predicted DLco between 40-60% inclusive. 
Table 1. Comparison of baseline clinical characteristics between subjects included in discovery and 
validation cohorts. 
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 Discovery Population Validation Population 
Group Variable 
Hazard Ratio 
(95% CI) P value 
Hazard Ratio 
(95% CI) P value 
Nordic Markers BGM 1.17 (0.53,2.58) 0.71 1.34 (0.92,1.97) 0.13 
 C1M 1.21 (0.66,2.22) 0.55 1.62 (1.14,2.31) 0.01 
 C3A 1.34 (0.95,1.88) 0.092 1.91 (1.06,3.46) 0.03 
 C3M 2.18 (0.95,5.00) 0.066 1.56 (0.94,2.59) 0.09 
 C5M 1.66 (0.95,2.91) 0.077 1.07 (0.66,1.72) 0.79 
 C6M 1.49 (0.86,2.56) 0.16 1.39 (0.93,2.06) 0.11 
 CRPM 3.74 (1.46,9.58) 0.006 1.87 (0.98,3.56) 0.06 
 ELM 0.96 (0.75,1.24) 0.78 ND ND 
 ELM2 1.00 (0.68,1.45) 0.99 ND ND 
 P3NP 1.48 (0.67,3.27) 0.33 ND ND 
 VICM 1.11 (0.83,1.49) 0.50 1.15 (0.92,1.43) 0.24 
 
Lung Function Measures % pred FVC 0.09 (0.03,0.27) <0.001 0.27 (0.10,0.70) 0.01 
 % pred DLco 0.19 (0.08,0.42) <0.001 0.18 (0.10,0.34) <0.001 
Table 2. Univariate analysis of overall survival by baseline measures in discovery and validation 
cohorts. FVC – forced vital capacity, DLco – diffusion capacity for carbon monoxide. Hazard ratios for 
the neoepitopes relate to the effect of a 1 unit increase in the variable whilst the hazard ratios for 
FVC and DLco relate to the effect of a two-fold increase in the explanatory variable.  
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Figure Legends 
Figure 1: Study population. A total of 214 individuals were recruited into the study (between 
September 2010 and March 2012) of whom 25 had a diagnosis of NSIP and the remainder were 
confirmed to have IPF (n=189). A Discovery Cohort based on disease severity as determined by 
composite physiological index (38.5% mildest; 25% moderate; 36.5% severest) was drawn from the 
first 100 subjects and the Validation Cohort (n=134: 14.6% mild; 71.5% moderate; 13.8% severe 
using the criteria applied to the discovery cohort) consisted of the subsequent 114 subjects plus the 
remaining subjects from the first 100 patients. Three subjects were excluded from the validation 
cohort (one was missing a baseline serum sample and two were lost to follow-up).  
Figure 2: Baseline comparison of neoepitope levels in healthy controls and IPF subjects with stable 
and progressive disease in the discovery cohort. Biomarker data from the Discovery Cohort is 
presented as means (ng/ml) and 95% confidence intervals adjusted for age and gender. Numbers in 
each group are; 20 healthy subjects (gender matched only) represented by ‘●’; 23 stable IPF 
represented by ‘■’ and 32 progressive IPF represented by ‘▲’. Disease progression was defined as 
all-cause mortality or ≥ 10% decline in FVC at 12 months. For ELM2 4% of values were imputed. For 
all other epitopes the imputation rate was <1%.  P values are provided where significant differences 
were observed between Healthy subjects and Stable IPF subjects (□); between healthy subjects and 
Progressive IPF (∆) and between stable IPF and Progressive IPF (◊).  
Figure 3: Comparison of neoepitope levels in healthy controls and IPF subjects with stable and 
progressive disease at baseline and at 1, 3 and 6 months post baseline in the validation cohort.  
Subjects were recruited into the PROFILE study within six months of diagnosis (baseline) and serum 
samples stored for biomarker analysis at baseline and at one, three and six months post baseline. 
Numbers at baseline were 50 healthy subjects (●); 60 IPF subjects with stable disease (■) and 71 
subjects with progressive IPF (▲). Biomarker data represent means (ng/ml) and 95% confidence 
intervals, adjusted for age and gender. Two subjects were excluded from analysis because of missing 
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longitudinal follow up and one subject because of missing baseline samples. For C5M 2% of values 
were imputed. For all other neoepitopes the imputation rate was <1%. P values are provided where 
differences were observed between stable and progressive disease at a particular time point ( ).  
Levels of BGM, C1M, C3A, C3M, C6M and CRPM increase over time in the subjects with progressive, 
but not stable, disease.  
Figure 4: Effect of 3 month change in neoepitope levels on overall survival. For all individual 
participants and each individual neoepitope the three month change in neoepitope level (Δ) was 
calculated as the slope of the best fit line through baseline, one month and three month values. 
Subjects have then been dichotomised into those with rising (Δ> 0ng/ml/month shown in red) and 
those with stable or falling (Δ≤ 0ng/ml/month shown in blue) neoepitope levels. The number of 
deaths in each group is shown for each biomarker. The Hazard Ratio (HR) represents the mortality 
risk in subjects with rising neoepitope levels (Δ> 0ng/ml/month) relative to subjects with stable or 
falling levels (Δ≤ 0ng/ml/month). The p-values presented are those for association between the 
individual, dichotomous marker and survival.   This association was significant for C1M, C5M, C6M 
and CRPM. 
Figure 5: Effect of the magnitude of 3 month change in neoepitope levels on overall survival.  The 
effect of different rates of neoepitope change was explored by using a range of threshold values of 
the biomarker gradient in order to dichotomizing the patients into a 'high' (gradient above 
threshold) or 'low' (gradient below threshold) group. The effect, on the hazard ratio, of 
dichotomising subjects at different available thresholds of 3-month neoepitope change is presented. 
The x-axis represents the threshold of the slope of the biomarker change that was used to 
dichotomise the patient population. The y-axis represents the hazard ratio plotted as base 2 log 
transformation of the unitary data. The data are expressed as mean hazard ratio with 95% 
confidence intervals for each threshold. For each threshold value on the x-axis, the hazard ratio 
plotted represents the risk for IPF subjects in "high" group vs "low" group. The upper and lower 
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extremes for each neoepitope have been limited to comparisons where there are at least 5 deaths in 
both the high and low groups. 
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